LEO LUZNIK to Ipilimumab
This is a "connection" page, showing publications LEO LUZNIK has written about Ipilimumab.
Connection Strength
0.113
-
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clin Cancer Res. 2018 08 01; 24(15):3519-3527.
Score: 0.113
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.